Abstract library

13 results for "Dromain C, Duvillard".
#282 Characteristics of Patients with Well-differentiated Metastatic Lung Neuroendocrine Tumors
Introduction: Characteristics of well-differentiated lung neuroendocrine tumors (WDLNET) are poorly characterized at the metastatic stage.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Cecile Chougnet
Authors:
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
Authors:
#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Cristina De Martino
Authors:
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
Authors:
#512 Epidemiology of Neuroendocrine Tumors in France: The PRONET Study
Introduction: Because of recent progress in neuroendocrine tumor treatment (NET), more data are required about this pathology in France.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Xavier Parot
Authors:
#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?
Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
Authors:
#714 Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy
Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Julien Hadoux
Authors:
#759 Inter-and Intra-Observers Reproducibility of MRI for the Measurement of NET Liver Metastases
Introduction: Assessment of treatment is based on metastases size measurement.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Julia Arfi Rouche
Authors:
#998 Intra and Interobserver Reproducibility of CT and MRI for Measurement of Liver Metastasis as a Basis of RECIST Evaluation in Patients with Neuroendocrine Tumors
Introduction: The reliability of RECIST evaluation in patients with NET has not yet been analyzed.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Julia Arfi Rouche
Authors:
#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data
Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Christine Massien
Authors:
Keywords: TGR, PFS